% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fuchs:284784,
      author       = {M. Fuchs and A. S. Jacob and H. Kaul and C. Kobe and G.
                      Kuhnert and T. Pabst and R. Greil and P. J. Bröckelmann and
                      M. S. Topp and M. Just and B. Hertenstein and M. Soekler and
                      M. Vogelhuber and J. M. Zijlstra and U. B. Keller and S. W.
                      Krause and U. Dührsen and J. Meissner and A. Viardot and
                      H.-T. Eich and C. Baues and V. Diehl and A. Rosenwald and I.
                      Buehnen and B. von Tresckow$^*$ and M. Dietlein and P.
                      Borchmann and A. Engert and D. A. Eichenauer},
      title        = {{F}ollow-up of the {GHSG} {HD}16 trial of {PET}-guided
                      treatment in early-stage favorable {H}odgkin lymphoma.},
      journal      = {Leukemia},
      volume       = {38},
      number       = {1},
      issn         = {0887-6924},
      address      = {London},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2023-02095},
      pages        = {160-167},
      year         = {2024},
      note         = {2024 Jan;38(1):160-167},
      abstract     = {The primary analysis of the GHSG HD16 trial indicated a
                      significant loss of tumor control with PET-guided omission
                      of radiotherapy (RT) in patients with early-stage favorable
                      Hodgkin lymphoma (HL). This analysis reports long-term
                      outcomes. Overall, 1150 patients aged 18-75 years with newly
                      diagnosed early-stage favorable HL were randomized between
                      standard combined-modality treatment (CMT) (2x ABVD followed
                      by PET/CT [PET-2] and 20 Gy involved-field RT) and
                      PET-2-guided treatment omitting RT in case of PET-2
                      negativity (Deauville score [DS] < 3). The study aimed at
                      excluding inferiority of PET-2-guided treatment and
                      assessing the prognostic impact of PET-2 in patients
                      receiving CMT. At a median follow-up of 64 months,
                      PET-2-negative patients had a 5-year progression-free
                      survival (PFS) of $94.2\%$ after CMT (n = 328) and $86.7\%$
                      after ABVD alone (n = 300; HR = 2.05 [1.20-3.51]; p =
                      0.0072). 5-year OS was $98.3\%$ and $98.8\%,$ respectively
                      (p = 0.14); 4/12 documented deaths were caused by second
                      primary malignancies and only one by HL. Among patients
                      assigned to CMT, 5-year PFS was better in PET-2-negative (n
                      = 353; $94.0\%)$ than in PET-2-positive patients (n = 340;
                      $90.3\%;$ p = 0.012). The difference was more pronounced
                      when using DS4 as cut-off (DS 1-3: n = 571; $94.0\%$ vs. DS
                      ≥ 4: n = 122; $83.6\%;$ p < 0.0001). Taken together, CMT
                      should be considered standard treatment for early-stage
                      favorable HL irrespective of the PET-2-result.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37845285},
      doi          = {10.1038/s41375-023-02064-y},
      url          = {https://inrepo02.dkfz.de/record/284784},
}